Surgical management of stage-2 medication-related osteonecrosis of the jaw with transplantation of human amniotic membrane: Preliminary results

Basit Öğe Kaydı
dc.authoridÇanakçi, F. Gülfeşan/0000-0001-7553-7062
dc.authorwosidEr, Nilay/HFI-7812-2022
dc.authorwosidÇanakçi, F. Gülfeşan/AAC-3449-2022
dc.contributor.authorCanakci, F. GulfeSan
dc.contributor.authorEr, Nilay
dc.contributor.authorDuygu, Gonca
dc.contributor.authorVarol, G. F. Usun
dc.date.accessioned2024-06-12T11:08:12Z
dc.date.available2024-06-12T11:08:12Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMedication-related osteonecrosis of the jaw (MRONJ) is a drug adverse reaction. Seven osteonecrosis areas in 5 cases were treated with stage-2 MRONJ using human amniotic membrane (HAM) transplantation after sequestrectomy. Patients were evaluated in terms of infection (pain, erythema, and pus), mucosal coverage, and pain at 1, 2, 4, 8, and 12 weeks. Patients who showed improvement (total mucosal coverage, no sign of infection and pain) at the end of 12 weeks were followed up every 8 weeks. Also, radiographic examinations (panoramic radiography at every 8 weeks, cone-beam computed tomography at every 6 months) were performed to evaluate bone destruction. Complete mucosal closure was achieved in 6 necrosis sites. In only 1 patient, mucosal coverage was not achieved. No pain and infection relapse were observed during the followups. HAM might be an effective material in terms of soft tissue healing and elimination of pain and infection for stage-2 MRONJ. Clinical Trials Registration Number: NCT04967963 (C) 2021 Published by Elsevier Masson SAS.en_US
dc.description.sponsorshipTrakya University, Scientific Research Project Department [2018/275]en_US
dc.description.sponsorshipThis study was supported financially by Trakya University, Scientific Research Project Department (2018/275).en_US
dc.identifier.doi10.1016/j.jormas.2021.09.011
dc.identifier.endpageE31en_US
dc.identifier.issn2468-8509
dc.identifier.issn2468-7855
dc.identifier.issue3en_US
dc.identifier.pmid34563730en_US
dc.identifier.scopus2-s2.0-85129908450en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE28en_US
dc.identifier.urihttps://doi.org/10.1016/j.jormas.2021.09.011
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22343
dc.identifier.volume123en_US
dc.identifier.wosWOS:000883690500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal Of Stomatology Oral And Maxillofacial Surgeryen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMedication-Related Osteonecrosis Of The Jawen_US
dc.subjectMRONJen_US
dc.subjectBisphosphonatesen_US
dc.subjectAmniotic Membraneen_US
dc.subjectMucosal Coverageen_US
dc.subjectPosition Paperen_US
dc.subjectDefectsen_US
dc.titleSurgical management of stage-2 medication-related osteonecrosis of the jaw with transplantation of human amniotic membrane: Preliminary resultsen_US
dc.typeEditorialen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu